Wednesday, August 17, 2022
Aug. 17, 2022

Linkedin Pinterest

CytoDyn continues COVID-19 treatment test

The Columbian

Vancouver-based biotechnology company CytoDyn announced Friday that it has now enrolled seven patients in a test to see if the company’s flagship treatment product can be used to effectively treat COVID-19.

The treatment is an antibody called leronlimab, originally created to treat HIV, but CytoDyn theorized that it could also function as an anti-inflammatory agent that could prevent COVID-19 patients from developing Acute Respiratory Distress Syndrome, a potentially lethal complication of COVID-19.

CytoDyn received permission from the Food and Drug Administration to fast-track a test, and it announced Friday that it has begun to receive results from the first four patients, all of whom are at a medical facility in New York.

The company also announced on Friday that it submitted another refinement to its proposal to the FDA for a broader clinical trial that would test 75 patients for up to six weeks.

Support local journalism

Your tax-deductible donation to The Columbian’s Community Funded Journalism program will contribute to better local reporting on key issues, including homelessness, housing, transportation and the environment. Reporters will focus on narrative, investigative and data-driven storytelling.

Local journalism needs your help. It’s an essential part of a healthy community and a healthy democracy.

Community Funded Journalism logo